Sign in
Taking peoplePhase 1

First-in-human (FIH), microdosing, non-randomized, clinical trial to investigate binding of positron emission tomography tracer [68Ga]Ga-DOTA-Cys-ATH001 targeting platelet derived growth factor receptor β in healthy subjects as compared to patients with metabolic dysfunction-associated steatohepatitis (MASH) and Primary Sclerosing Cholangitis binding (PSC, liver) and patients with fibrostenotic Crohn’s disease (CD, gastrointestinal tract [GI])

Key facts

Who runs it
Antaros Medical AB
Where
Sweden3 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 1
People taking part
36 people, planned
Started
19 Aug 2024
Expected to end
31 Dec 2026
Type of study
Interventional
Record updated
3 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
3 November 2026